BPGbio to Present Novel E2-Based TPD Program at 5th Annual Summit BPGbio, Inc., a leading biology-first, AI-powered, clinical-stage biopharmaceutical company focused on mitochondrial biology and protein homeostasis, has announced its…
Optum Rx to Modernize Pharmacy Payment Models Rising drug prices set by pharmaceutical manufacturers are placing significant financial strain on pharmacies across the United States. As the cost of prescription…
MiNA Therapeutics Adds Norbert Bischofberger to Board, Bríd Ryan as CSO MiNA Therapeutics Limited, a leader in the development of small activating RNA (RNAa) therapeutics, has announced key leadership changes…
Triastek announced that on February 27, 2025, its proprietary 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product, T20G, received Investigational New Drug (IND) clearance from the U.S. Food and Drug…
ICON Fully Integrates Medidata Clinical Data Studio Medidata, a Dassault Systèmes brand and a leading provider of clinical trial solutions for the life sciences industry, has announced a significant partnership…
Scholar Rock Presents Comprehensive Phase 3 SAPPHIRE Trial Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference Scholar Rock, a late-stage biopharmaceutical company committed to advancing groundbreaking treatments…
Faeth Therapeutics & GOG-F Launch Phase 2 Trial for Sapanisertib-Serabelisib in Endometrial Cancer Faeth Therapeutics (Faeth), a clinical-stage biotechnology company dedicated to pioneering novel metabolism-based therapeutic strategies, and The GOG…
Biote Announces Fourth Quarter and Full-Year 2024 Financial Results Biote, a leading provider of personalized hormone optimization and therapeutic wellness solutions, has released its financial results for the fourth quarter…
SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presented late-breaking scientific…
Merck’s Phase 3 Trials Show DOR/ISL Maintains HIV-1 Suppression at 48 Weeks Merck, known as MSD outside of the United States and Canada, has announced promising results from two pivotal…
Gilead Unveils New HIV Treatment Data at CROI 2025 Gilead Sciences, Inc. has unveiled a significant array of late-breaking data and multiple oral presentations from its groundbreaking HIV treatment portfolio…
City of Hope’s Phase 1 Trial Featured at SSO Annual Meeting City of Hope’s groundbreaking Phase 1 clinical trial has demonstrated promising results for patients suffering from colorectal and appendiceal…